Oil prices rise from over 1-mth low with Russia crude buyer sanctions in focus
BioSig Technologies, Inc., a medical device company, has been notified by the Nasdaq Stock Market that it is currently not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The notice, received on Monday, April 11, 2025, indicated that BioSig’s common stock, currently trading at $0.58, had closed below the required minimum bid price of $1.00 per share for 30 consecutive business days. According to InvestingPro data, the stock has seen significant volatility, trading between $0.20 and $2.57 over the past 52 weeks.
The company, which is listed under the ticker (NASDAQ:BSGM), now has a 180-day period, until October 8, 2025, to regain compliance with the minimum bid price rule. To achieve this, BioSig’s common stock must maintain a closing bid price of at least $1.00 for a minimum of ten consecutive business days during this period. Despite recent challenges, InvestingPro data shows the stock has gained 36% in the past week and over 105% in the last six months.
If BioSig fails to meet the requirement by the end of the compliance period, it may be granted an additional 180 days, provided it meets the other initial listing standards for The Nasdaq Capital Market, except for the bid price. This extension would potentially involve implementing a reverse stock split to increase the per-share price.
The letter from Nasdaq has no immediate effect on BioSig’s listing, and its stock will continue to trade on The Nasdaq Capital Market, subject to the company’s compliance with other listing requirements.
The company, headquartered in Los Angeles, California, specializes in the development of advanced electromedical equipment. While BioSig’s business operations continue, InvestingPro analysis indicates some financial challenges, with an EBITDA of -$17.34M and a current ratio of 0.5, suggesting potential liquidity concerns. The company has not commented on any plans to address the bid price deficiency.
This news is based on a recent SEC filing by BioSig Technologies, Inc.
In other recent news, BioSig Technologies, Inc. has announced significant progress towards meeting Nasdaq’s compliance requirements. The company disclosed that its recent capital-raising efforts might have elevated its stockholders’ equity to at least $2.5 million, meeting Nasdaq’s Equity Rule threshold. BioSig has been actively working to align with these standards after being granted a grace period until March 2025. To bolster its financial position, the company sold over 5 million shares, raising approximately $4.85 million through agreements with H.C. Wainwright & Co., LLC, and accredited investors.
Additionally, BioSig entered into an Equity Subscription Agreement with Lind Global Fund III, LP, allowing the sale of up to $5 million in common stock over the next 36 months. These actions have led the company to believe it has satisfied the stockholders’ equity requirement. BioSig is now awaiting formal confirmation from Nasdaq regarding its compliance. Should Nasdaq confirm compliance, BioSig will be subject to ongoing monitoring to maintain the necessary financial standards. Failure to comply in its next periodic report could result in delisting from the Nasdaq exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.